Literature DB >> 33161963

Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies.

Elisa Cordero1, Walter Goycochea-Valdivia2, Ana Mendez-Echevarria3, Luis M Allende4, Laia Alsina5, Maria Bravo García-Morato6, Juana Gil-Herrera7, Carlota Gudiol8, Oscar Len-Abad9, Francisco López-Medrano10, David Moreno-Pérez11, Patricia Muñoz12, Peter Olbrich2, Silvia Sánchez-Ramón13, Pere Soler-Palacín14, Clara Aguilera Cros15, Juan Ignacio Arostegui16, Isabel Badell Serra17, Javier Carbone18, Jesús Fortún19, Luis I Gonzalez-Granado20, Eduardo López-Granados21, José Manuel Lucena22, Rocío Parody23, Jan Ramakers24, José R Regueiro25, Jacques G Rivière14, Cristina Roca-Oporto26, Rebeca Rodríguez Pena21, Juan Luis Santos-Pérez27, Carlos Rodríguez-Gallego28, Olaf Neth2.   

Abstract

Primary immunodeficiencies (PIDs) are rare, undiagnosed and potentially fatal diseases. Clinical manifestations of PID can be fatal or leave sequelae that worsen the quality of life of patients. Traditionally, the treatment of PIDs has been largely supportive, with the exception of bone marrow transplantation and, more recently, gene therapy. The discovering of new affected pathways, the development of new molecules and biologics, and the increasing understanding of the molecular basis of these disorders have created opportunities in PIDs therapy. This document aims to review current knowledge and to provide recommendations about the diagnosis and clinical management of adults and children with PIDs based on the available scientific evidence taking in to account current practice and future challenges. A systematic review was conducted, and evidence levels based on the available literature are given for each recommendation where available.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Haematopoietic progenitors transplantation; Primary immunodeficiencies; Treatment; Vaccination

Mesh:

Year:  2020        PMID: 33161963     DOI: 10.1016/j.jaip.2020.05.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  2 in total

Review 1.  Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.

Authors:  Olaf Neth; Peter Olbrich; Angela Deyà-Martínez; Jaques G Rivière; Pérsio Roxo-Junior; Jan Ramakers; Markéta Bloomfield; Paloma Guisado Hernandez; Pilar Blanco Lobo; Soraya Regina Abu Jamra; Ana Esteve-Sole; Veronika Kanderova; Ana García-García; Mireia Lopez-Corbeto; Natalia Martinez Pomar; Andrea Martín-Nalda; Laia Alsina
Journal:  J Clin Immunol       Date:  2022-04-29       Impact factor: 8.542

Review 2.  Inborn Errors of Immunity: how to diagnose them?

Authors:  Anete Sevciovic Grumach; Ekaterini Simões Goudouris
Journal:  J Pediatr (Rio J)       Date:  2021-01-02       Impact factor: 2.990

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.